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Periodontitis is a chronic infectious disease of the 
supporting tissues of the teeth. Bacterial infection can 
cause periodontal tissues to become inflamed and 
eventually destroyed by the inflammatory process. If 
we do not treat the disease, teeth lose their 
ligamentous support to the alveolar bone. Once the 
alveolar bone is resorbed, the teeth become mobile and 
are eventually lost.1 In almost all types of periodontitis, 
both the oral microflora and the human response play 
significant purpose in the commencement and 
progression of these diseases. 
 
Use of adjunctive various host-modulating agents like 
non-steroidal anti-inflammatory drugs, 
subantimicrobial dose doxycycline, bisphosphonates, 
selective estrogen receptor modulators, resolvins, 
lipoxins, to mention a few, are estimated. More 
recently, statins, which are hypolipidemic drugs of 
choice, are being explored as anti-inflammatory and 
osteoinductive agents. The anti-inflammatory effects 
that are postulated to provide cardioprotective benefits 
beyond those attributable to the hypolipidemic effects 
alone are referred to as pleiotropic effects.2 
 
5-hydroxymethylglutaryl-CoA reductase inhibitors, 
usually referred to as statins, decrease cholesterol 
levels by inhibiting cholesterol biosynthesis. This will, 
in turn, reduce the chances of cardio-vascular issues, as 
do other drugs that reduce the cholesterol levels in 
serum.    Their     activity     essentially     consists      of  
 
competitively  inhibiting  3-hydroxy-3 methyl glutaryl 
co-enzyme A reductase  (HMG CoA)  that will inhibit 
cholesterol synthesis. It is evident that statins exert 
several vascular actions that are not lipid lowering.3 
Statins have proven to have significant  anti-oxidative 
and  anti- inflammatory properties.4 
 
 
It has pleiotropic effects and anti-Inflammatory 
property, that is associated with the reduction in 
isoprenoids that is accountable for post-translational 
modification of proteins.5 Among these proteins, the 
reduced prenylation and small G-proteins activity (Ras, 
Rho) appears significant. At a minimum, the effects 
include a reduced inflammation in vessels by inhibiting 
the macrophage activation and proliferation; inhibition 
of secretion of MMP- matrix metallo-proteinases; 
inhibition of smooth vascular muscle proliferation and 
platelet activation; promotion of neovascularization 
through direct angiogenesis or mobilization of 
endothelial progenitor cells; antioxidant effect through 
downregulation of angiotensin 1 receptor expression 
and inhibition of Nicotinamide Adenine Dinucleotide 
Phosphate (NADPH) oxidase activity.6,7 
 
The protective cardiovascular effect partly comes from 
anti-inflammatory property such as Inhibiting TNF-a 
and MMP-9. MMP-9 and TNF-alpha are responsible for 
tissue destruction in chronic periodontitis.   Moreover,    
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by stimulating the bone morphogenetic protein-2 
production.8 Hence, it seems possible that statins 
might be protective against cardiovascular problems 
and chronic periodontitis. Various animal studies 
showed Simvastatin (SMV) aids in bone regeneration 
and shows  anti-inflammatory effect when delivered or 
applied locally.9 
 
Our study has been designed to assess the efficacy of 
locally delivered drug of Simvastatin 1.2% into the deep 
periodontal pocket stimulating a substantial increase 
in pocket probing depth (PPD) reduction, relative 
clinical attachment level (CAL) gain as compared to the 
placebo gel as an adjunct to (SRP) scaling and root 
planing in the management of Periodontitis. 
 
MATERIALS AND METHODS 
Source of data: The investigation was a comparative 
assessment of the efficiency of an indigenously 
developed Locally Delivered Drug (LDD) simvastatin 
conducted out in the Department of Periodontics, in 
ITS Dental College. After ethical approval was given, 
written informed consent was signed by all study 
participants. The study was carried out from January 
2018 to December 2018. 
 
Formulation and in vitro evaluation of gels 
containing simvastatin: Methylcellulose in situ gel 
was prepared by adding biocompatible solvent to the 
appropriate amount of methylcellulose. The solution 
was heated to 50–60 °C and then agitated with 
mechanical shaker in order to get a clear solution. A 
pre- determined amount of Simvastatin was poured to 
the solution and then dissolved fully. A homogeneous 
phase of polymer, solvent, and drug. A 1.2% SMV in-
situ gel was ready.  
 
Local Drug Delivery: For standardization, 10 mL 
prepared SMV gel (1.2 mg/ 0.1 mL) was injected into the 
pockets using a syringe with a blunt cannula) (figure 2).  
Patients were directed to abstain from chewing hard or 
sticky foods, brushing near the treated areas or using 
any interdental aids for one week. Adverse effects were 
noted at recall visits, each patient was reinstructed for 
proper oral hygiene procedures at recall visits, where 
any supragingival deposits were removed. 
 
Selection Criteria: Patients with PD ±5 mm or relative 
CAL ±4 mm with no history of periodontal therapy or 
use of antibiotics in the last 6 months, with presence of 





parameters were assessed at six sites per tooth using a 
periodontal probe. Individuals with known systemic 
disease, patients with known or suspected allergy to 
the Simvastatin, those on systemic Simvastatin  
therapy, individuals with hyperlipidemia or individuals 
who process a lipid-reducing diet, individuals with 
Aggressive periodontitis, patients who use tobacco, 
alcoholics,  immunocompromised individuals, and 
pregnant or lactating females were not included in the 
study. Also, teeth with furcation defects, gingival 
recession, endodontic (pulpal) involvement, and third 






25 patients were able to fit in the inclusion criteria with 
50 sites. All the parameters- site specific plaque index, 
modified sulcular bleeding index, pocket probing 
depth, relative attachment level were checked at 
baseline. (figure 1). Random allotment was done using 
the coin toss method, and groups were assigned. Group 
1 was the control Group, where the scaling and root 
planing were done along with placebo gel placement. 
Group 2 included patients where along with scaling and  
Figure 1. Pre-Operative Records of Indices and 
Clinical Parameters 
Figure 2. Local Drug Delivery – 1.2 % Simvastatin 
in the Pocket after SRP 
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root planing, 1.2 % Simvastatin gel was placed. COE 
pack was placed for 1 week.  All the parameters were 







Statistical Analysis: Statistical investigation of the 
data was carried out using Statistical Package for the 
Social Sciences (SPSS) software 16. Student’s paired t-
test was applied to test the mean changes in scores at 
different time points within each study group. 
(ANOVA) One-way analysis of variance was carried out 
to compare the mean scores between different study 
groups. Tukey’s “honestly significant difference” 
procedure was carried out to identify the significant 
groups if the test of significance in one-way ANOVA 
was significant. P < 0.05 was considered as the level of 
significance in this study.  
   
RESULT 
Twenty-five (two sites per participant) subjects were 
able to complete the study (table 1)  All participants 
accepted the drug very well with no complications or 
adverse reactions to the drug. Soft tissues healed 
uneventfully, and no major visual differences were 
noted. 
 
The two groups revealed improvement in site-specific 
PI score, but there wasn’t statistical substantial 
difference in site-specific PI score among the 2 groups 
at any visit (tables 1 & 2). This specifies that both the 
groups kept comparable levels of dental hygiene during 
the study. mSBI in the both groups showed no 
difference at baseline, but it was considerably reduced 
in the SMV group compared with placebo group at 3 
and 6 months (P <0.05) (table 1). Clinical parameters- 
(PPD) pocket probing depth and relative CAL also 
showed no substantial difference between the 2 groups 
at baseline. However, the SMV group showed 

















































relative CAL gain at 3 and 6 months compared to the 
control group at P <0.001 (table 3). 
 
DISCUSSION 
Our present research evaluated the clinical efficiency 
of 1.2 % SMV in- situ gel in adjunctive measure to SRP 
(scaling and root planing) in treatment of patients with 
CP and showed substantial enhancement in 
parameters compared to the placebo gel. There are very 
few studies recording the use of 1.2 % SMV gel as local 
drug delivery to treat patients with periodontitis. 
Therefore, a straightforward comparison with other 
studies is not practical.  
 
The mean site-specific plaque index in the group -1 
(control group at baseline was 2.8± 0.2261 mm, after 3- 
months was 1.35±0.1945 mm, and 1.30±0.1945 mm after 
6 months. The mean reduction in site-specific plaque 
index from the baseline to 3 month and 6 months was 
statistically significant in our control group. The mean 
site-specific plaque index at baseline was 2.14±0.1845 
mm, after 3 months was 1.18±0.1370 mm, and 
1.05±0.1347 mm after 6 months in the test group. The 
test group showed a statistically significant mean 
reduction in site-specific plaque index from baseline to 
3 and 6 months. The site-specific plaque index of both 
groups reduced throughout the time intervals. 
However, the SMV group displayed a more substantial 
reduction in the site-specific plaque index in the test 
group   than    the    control     group (Group-1)     upon     
 
Figure 3. Recoding of All the Parameters At 3 
Months, And 6 Months 
Table 1. Subjects and their periodontal defect characteristics 
at baseline [Values are presented as mean ± SD; Group 1: 
Control site: SRP was performed, with placement of placebo 
gel; Group 2: Test site: SRP was performed with placement of 
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 VARIABLE BASELINE 3 
MONTHS 













GROUP 1 2.8±0.2261 1.35±0.1945 1.30±0.1945 1.45±0.031 0.0045 1.5±0.195 0.0048 
GROUP 2 2.14±0.1845 1.18±0.1370 1.05±0.1347 0.96±0.047 0.0023 1.09±0.137 0.0032 





GROUP 1 1.31±0.1080 1.16±0.0589 1.03±0.0876 0.15±0.049 0.0042 1.16± .020 0.0045 
GROUP 2 1.37±0.1287 0.73±0.1566 0.57±0.1703 0.64±0.027 0.0024 0.8±0.111 0.00324 






In the control group, the mean modified sulcular 
bleeding index at baseline was 1.31±0.1080 mm. After 3 
months it was 1.16±0.0589 mm and after 6 months was 
1.03±0.0876 mm. The control group showed substantial 
reduction in mean modified sulcular bleeding index 
from baseline to 3 months, and then to 6 months. In 
the test group, the mean modified sulcular bleeding 
index at baseline was 1.37±0.1287 mm. After 3 months it 
was 0.73±0.1566 mm and after 6 months, 0.57±0.1703 
mm. A statistically substantial mean reduction 
occurred in the test group's modified sulcular bleeding 
index from baseline to 3 and 6 months. A decrease in 
the mean modified sulcular bleeding index was noted 
in both groups from baseline to the different time 
intervals. However, the SMV group displayed a more 
significant reduction in the mean modified sulcular 
bleeding index in the test group than the control group 
on the intergroup comparison. 
 
In our present study – group 1 (control group), the 
mean Pocket Probing Depth (PPD) at baseline was 
5.20±0.516 mm. After 3 months it was 3.80±0.542 mm 
and after 6 months was 3.70± .583 mm. The control 
group showed a statistically significant mean reduction 
in mean pocket probing depth from baseline to 3 
months and 6 months. The test group showed a mean 
pocket probing depth at baseline of 5.40±0.445 mm. 
After 3 months it was 3.20±0.243 mm and after 6 
months it was 2.84± .766 mm. The test group displayed 
a statistically significant mean reduction of pocket 
probing depths from baseline throughout our specified 
time intervals. A decline in the mean pocket probing 
depths were recorded in both groups from baseline to 
till both the time intervals. However, the SMV group 
displayed a more substantial reduction in the test 
group than the control group on the intergroup 
comparison. 
 
In the control group, the mean relative (rCAL) clinical 
attachment level at baseline was 08.70±0.675mm. 
Subsequently 3 months later it was 7.20±0.632 mm and 
after 6 months it was 6.84±0.223 mm. The control 
group showed a significant change in mean relative 
clinical attachment level from baseline to 3 and 6 
months. The mean (rCAL ) relative clinical attachment 
level in the test group at baseline was 08.90±0.756 mm. 
3 months later, it was 6.90±0.483 mm and after 6 
months it was 6.63±0.236 mm. The Group 2 showed 
statistically substantial changes in the mean (rCAL) 
relative clinical attachment level from baseline to 3 and 
6 months. A reduction in the (rCAL)relative clinical 
attachment level have been noted in 2 groups from 
baseline to the different time intervals. However, the 
SMV group displayed a more significant reduction in 
the test group than the control group on the intergroup 
comparison. 
 
The test group - 2 shows a more drastic decrease in 
indices, (PPD) pocket probing depth, and (Rcal) 
relative attachment level than the control group. The 
gingival bleeding index reduced from baseline to 6 
months, suggesting that simvastatin has an anti-
inflammatory effect. A comparable anti-inflammatory 
effect of SMV was noted by Lindy et al.10 in patients 
with chronic periodontitis on systemic statin therapy. 
The patients taking statins had 37% fewer periodontal 
pockets than those not taking statin medication. 
Sakoda et al.11 demonstrated the anti-inflammatory 
effect of SMV on oral epithelium cells, evidently 
involving Rac1 guanosine triphosphatase inhibition, 
and noted reduced IL-6 and IL-8 production. However, 
the scores of PI were also lower for both the respective 
groups. Considering that both groups had better 
plaque control (table 2), any reduction of gingival 
bleeding may be attributable to the better plaque 
control only and not by using the SMV. 
Table 2. Plaque Index and Modified Bleeding Index scores at baseline, 3 months and 6-month after SRP. [Values are 
presented as mean ± SD] 
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GROUP 1 5.20±0.516 3.80±0.542 3.70± .583 1.40±0.026 0.048 1.5±0.067 0.0049 
GROUP 
2 
5.40±0.445 3.20±0.243 2.84± .766 2.20±0.202 0.032 2.56±0.245 0.0036 




GROUP 1 08.70±0.675 7.20±0.632 6.84±0.223 1.5±0.043  1.86±0.45 0.048 
GROUP 
2 
08.90±0.756 6.90±0.483 6.63±0.236 2.00±0.273  2.27±0.48 0.032 




Similarly, PPD reduction was significant from baseline 
to 6 months and substantial difference among all 
groups at any interval of time. The reduction in the 
RALs at the end of the 6 month period was statistically 
relevant for the test groups and a less significant 
reduction for the control group, suggesting a more 
consistent outcome with statins, even though there is a 
noticeable difference among the three groups at any 
stage. Similar effects were recorded in the studies by 
Thorat and Pradeep12,13 and Rao et al.14, who reported 
significant favorable alterations in the PPD and 
attachment levels in the Group -2 in contrast with the 
control group. 
 
The sound effects of SRP are profound about clinical 
improvement and microbial suppression that the 
remaining dynamic range of disease expression or 
margin for additional clinical improvement is too small 
to measure the effects of any additional therapy. Thus, 
using anti-inflammatory drugs adjunctively to 
debridement therapy is ill-advised from an 
experimental design standpoint.2 Although this 
combined therapy may ultimately be preferred for 
those who possess a hyper-inflammatory phenotype, it 
is not ideal from a regulatory or drug development 
standpoint. Logically, this places the timing for such 
drugs either before the disease develops, as a 
preventive measure, or after debridement. Research 
has proved the dual relationship between periodontal 
disease and hyperlipidemia. It may very well prove that 
systemic disease can predispose to an oral infection, 
and once this oral infection is significant, it can 
exacerbate the systemic disease.15,16 Periodontitis leads 
to worsening of lipid metabolism. Likewise, 
periodontal inflammation is related with the worsening 
of a hyperlipidaemic state by increasing the gingival 
crevicular fluid and proinflammatory cytokines.18 In a 
study conducted to assess the effect of improved 
periodontal health following periodontal treatment on 
metabolic lipid control of patients on anti-lipemic 
treatment, it was seen that enhanced periodontal 
health can affect metabolic control of hyperlipidemia 
and can be considered as an adjunct to the measures of 
hyperlipidemic patient care which are standardly 
used.18 Hence, statin as an adjunct to SRP may play a 
role in management of CP as well as hyperlipidemia. 
 
Comparing systemic regimen with  local delivery, the 
latter may offer essential benefits in terms of few 
adverse reactions and better patient compliance, as 
stated in the previous study.19 
  
CONCLUSION 
This study demonstrates that locally delivered gel of 
1.2% SMV into periodontal pockets, periodontitis 
patients stimulates a substantial benefits in the PD 
reduction, Clinical attachment gain as opposed to 
placebo gel as an adjunctive measure to SRP. Hence 
this will take periodontal healing in patients at risk for 
periodontal destruction in a new direction. 
Nevertheless, long-term, multicentre randomized, 
controlled clinical trials are necessary to establish the 
clinical, histological, and radiographical consequence 
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